03 Apr 2018

Mereo BioPharma Group plc

("Mereo" or the "Company" or the "Group")

Mereo BioPharma publishes its Annual Report for the Year Ended December 31, 2017

London, April 3, 2018 – Mereo BioPharma Group plc (AIM: MPH), a multi-asset biopharmaceutical company focused on the acquisition, development and commercialisation of innovative therapeutics that aim to improve outcomes for patients with rare and specialty diseases, today confirms that its Annual Report and Accounts for the year ended December 31, 2017 has been published on the Company website at www.mereobiopharma.com and will shortly be posted to those shareholders who have not elected to receive electronic communication.

The Annual General Meeting will be held on June 21, 2018 at 11.30am at the offices of Latham & Watkins LLP, 99 Bishopsgate, London EC2M 3XF. Notice of the meeting and related documents will be posted to shareholders in due course.

FOR FURTHER ENQUIRIES:

Mereo BioPharma Group plc
Denise Scots-Knight, Chief Executive Officer
Richard Jones, Chief Financial Officer
+44 (0)333 023 7319

Nominated Adviser and Joint Broker
Cantor Fitzgerald Europe
Phil Davies
Will Goode
+44 (0)20 7894 7000

Joint Broker
RBC Capital Markets
Rupert Walford
Laura White
+44 (0)20 7653 4000

UK Public Relations Advisor to Mereo Biopharma
FTI Consulting
Ben Atwell
Simon Conway
Brett Pollard
+44 (0)20 3727 1000

US Public Relations Advisor to Mereo Biopharma
Burns McClellan
Lisa Burns
Steven Klass
+01 (0) 212 213 0006

ABOUT MEREO

Mereo is a multi-asset biopharmaceutical company focused on the acquisition, development and commercialization of innovative therapeutics that aim to improve outcomes for patients with rare and specialty diseases. The portfolio consists of four clinical-stage product candidates, each of which were acquired from large pharmaceutical companies: BPS-804 for the treatment of osteogenesis imperfecta; AZD-9668 for the treatment of severe alpha-1 antitrypsin deficiency; BCT-197 for the treatment of acute exacerbations of chronic obstructive pulmonary disease, or AECOPD; and BGS-649 for the treatment of hypogonadotropic hypogonadism (“HH”) in obese men. Each of the Company’s product candidates has generated positive clinical data for Mereo’s target indication or in a related indication. The Company’s strategy is to selectively acquire product candidates that have already received significant investment from pharmaceutical companies and that have substantial preclinical, clinical and manufacturing data packages. Since inception the Company has commenced large, randomized, placebo-controlled Phase 2 clinical trials for three of the product candidates and announced positive top-line results from its Phase 2 clinical trial of BCT-197 as an acute therapy for patients with AECOPD in December 2017 and positive top-line data from its Phase 2b dose-ranging study with BGS-649 for the treatment of HH. The Company intends to commence additional late-stage clinical trials in 2018.